Stockchase Opinions

Jason Donville Cipher Pharmeuticals CPH-T Unspecified Jan 06, 2025

It could become the next Paladin. It has great management and ownership along with a good outlook. It made a big acquisition in the U.S. and if the first two quarters go well the stock could go up.

$14.630

Stock price when the opinion was issued

Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK

This company has been beaten down recently due to a current takeover project and he feels there has been one shareholder putting pressure on the stock. He has been buying more and would buy more.

PAST TOP PICK

(A Top Pick March 26, 2018. Down 16%). This initially popped higher but they preannounced a poor quarter because the market had been stuffed by a promotion. This quarter will be a little weak for the same reason but after that, it will do better. Cipher historically focused on dermatology. With their purchase of Cardiome Pharma Corp’s Canadian assets, they will now also be focused on arrhythmia and other cardiovascular conditions addressed by Cordiome’s drugs. He loves Cipher here. He thinks it is trading at half what specialty pharma companies, like Knight, sell for. He sees this as a good takeover target for Knight and sees it as a potential double.

TOP PICK

This is a specialty pharma company. They have been focused on dermatology products, the lead being Absorbica. He’s excited by their development pipeline. They bought the Canadian assets of Cardiome and have successfully integrated them. This came with tax losses along with the pipelines. Together, they help make Cipher incredibly cheap at its current price. There was an issue with inventory of their US partner, but that has now been resolved. He expects the recovery to show good earnings momentum for the back half of this year, then the release of new products. The company has dropped from $18--it was caught up in the run-up of prescription prices (Valeant) and then the run-down. While their prices were high, they tried to get into the US in a big way, and that failed. That cost them about $10 million and hurt their share price, but that failure is long past. He likes it a lot at its current price. (Analysts’ price target is $6.06)

PAST TOP PICK
(A Top Pick Mar 26/18, Down 51%) It's plunged since the spring, treated unfairly by the market. (He explains why later in the show.)
TOP PICK
It was treated unfairly by its U.S. partner and the market. In 2017, CPH heavily promoted their big product and so they gained a lot of market share. But when they cut their promotion, there was also an inventory adjustment. So, demand went down way more than they should have. He thinks they will rebound in the next few quarter. It's also a take-over candidate. There's no cyclicality to this business either. (Analysts’ price target is $5.06)
PAST TOP PICK
(A Top Pick Mar 26/18, Down 54%) He slightly reduced his position, but still holds it. They got into a business agreement with Sun Pharma, a bigger company, that was distributing one of the biggest drugs. They did a big promotion last year and the stock did very well, but they stopped promoting it. The inventory built up and their orders to Cipher dwindled to almost nothing. CPH stock got punished. They've since solved it with a long-term supply agreement. Also, they have two new drugs approved in 2018 with at least three more in 2019. The founder just bought a bunch of shares, which is a good sign.
PAST TOP PICK
(A Top Pick Nov 27/18, Down 42%) A real dog, and he sold part of it late last year. He can't talk about it much.
PAST TOP PICK
(A Top Pick Nov 27/18, Down 44%) Lot of value still, but they completely replaced management and are looking to sell off parts or all of the business. Wait till that passes.
PAST TOP PICK
(A Top Pick Dec 20/18, Down 40%) It had a good turn in January. Beaten down stocks can have a nice bounce in January.